Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-03 7:04 pm Purchase | 2025-02-27 | 13D | BiomX Inc. PHGE | James E. Flynn | 15,558,445 9.990% | 0 (+0.00%) | Filing History |
| 2025-02-25 9:18 pm Sale | 2025-02-21 | 13D | Singular Genomics Systems, Inc. OMIC | James E. Flynn | 1,000 100.000% | -248,495 (-99.60%) | Filing History |
| 2025-02-13 09:40 am Sale | 2025-02-13 | 13G | DocGo Inc. DCGO | James E. Flynn | 5,051,500 4.950% | -4,014,638 (-44.28%) | Filing History |
| 2025-02-13 09:39 am Purchase | 2024-12-31 | 13G | Indivior PLC INDV | James E. Flynn | 8,883,160 7.160% | 1,519,950 (+20.64%) | Filing History |
| 2025-02-13 08:59 am Sale | 2024-12-31 | 13G | Ventyx Biosciences, Inc. VTYX | James E. Flynn | 534,737 0.760% | -6,180,764 (-92.04%) | Filing History |
| 2025-02-13 08:58 am Sale | 2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD | James E. Flynn | 0 0.000% | -4,133,000 (Position Closed) | Filing History |
| 2025-02-13 08:57 am Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | James E. Flynn | 0 0.000% | -5,312,733 (Position Closed) | Filing History |
| 2025-02-13 08:57 am Sale | 2024-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 3,133,011 2.630% | -3,096,623 (-49.71%) | Filing History |
| 2025-02-13 08:56 am Sale | 2024-12-31 | 13G | Alignment Healthcare, Inc. ALHC | James E. Flynn | 7,304,302 3.810% | -3,561,211 (-32.78%) | Filing History |
| 2025-02-13 08:55 am Sale | 2024-12-31 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 23,582,278 27.590% | -1,997,612 (-7.81%) | Filing History |
| 2025-01-28 5:40 pm Sale | 2025-01-27 | 13D | Acutus Medical, Inc. AFIB | James E. Flynn | 5,492,725 9.100% | -4,213,132 (-43.41%) | Filing History |
| 2025-01-23 9:16 pm Unchanged | 2025-01-21 | 13D | Acutus Medical, Inc. AFIB | James E. Flynn | 9,705,857 9.100% | 0 (Unchanged) | Filing History |
| 2024-12-26 8:55 pm Unchanged | 2024-12-22 | 13D | Singular Genomics Systems, Inc. OMIC | James E. Flynn | 249,495 6.620% | 0 (Unchanged) | Filing History |
| 2024-12-16 9:52 pm Purchase | 2024-12-12 | 13D | Acutus Medical, Inc. AFIB | James E. Flynn | 9,705,857 9.100% | 28,000 (+0.29%) | Filing History |
| 2024-11-15 6:03 pm Purchase | 2024-11-08 | 13G | Indivior PLC INDV | James E. Flynn | 7,363,210 5.800% | 7,363,210 (New Position) | Filing History |
| 2024-11-14 09:56 am Purchase | 2024-09-30 | 13G | DocGo Inc. DCGO | James E. Flynn | 9,066,138 8.880% | 3,745,999 (+70.41%) | Filing History |
| 2024-11-14 09:55 am Sale | 2024-09-30 | 13G | Catalyst Pharmaceuticals, Inc. CPRX | James E. Flynn | 6,229,634 5.220% | -2,659,267 (-29.92%) | Filing History |
| 2024-11-14 09:03 am Sale | 2024-09-30 | 13G | AdaptHealth Corp. AHCO | James E. Flynn | 23,758,393 7.220% | -3,896,530 (-14.09%) | Filing History |
| 2024-11-14 09:02 am Sale | 2024-09-30 | 13G | Verastem, Inc. VSTM | James E. Flynn | 0 0.000% | -1,538,461 (Position Closed) | Filing History |
| 2024-11-14 09:01 am Sale | 2024-09-30 | 13G | Nuo Therapeutics, Inc. AURX | James E. Flynn | 1,026,324 2.200% | -1,156,840 (-52.99%) | Filing History |